THE EFFECT OF DIFFERENT TB DRUGS AND ANTIMICROBIAL AGENTS ON THE EFFICIENCY OF TREATMENT OF TUBERCULOSIS PATIENTS WITH MULTIPLE DRUG RESISTANCE
https://doi.org/10.21292/2075-1230-2017-95-10-9-15
Abstract
Objective of the study: to study the effect of specific TB drugs and antimicrobial agents constituting chemotherapy regimens on the efficiency of treatment of tuberculosis patients with various patterns of multiple drug resistance.
Subjects and Methods. 412 pulmonary tuberculosis patients with bacillary excretion and various patterns of multiple drug resistance were enrolled into the study (117 patients with MDR TB (non pre-XDR and non-XDR); 120 patients with pre-XDR TB and 175 with XDR TB). Patients in the subgroups were compatible regarding sex and age. The patients were prescribed regimens including 5-6 drugs in accordance with their drug resistance pattern. The time of sputum conversion (by culture) versus the year of treatment was selected as a surrogate endpoint. The effect of specific TB drugs and antimicrobial agents on treatment efficiency was assessed through calculation of odds ratio (OR) of achieving a surrogate endpoint in the patients receiving and not receiving a certain drug.
Results. In the subgroup of pre-XDR TB, the following drugs demonstrated the valid increase of odds of sputum conversion: ethambutol (OR 11.8), pyrazinamide (OR 10.2), moxifloxacin (OR 7.8), capreomicin (OR 4.41). Sputum conversion was achieved in all 11 patients treated with bedaquiline.
In the subgroup of XDR TB, the following drugs provided a positive effect on the achievement of sputum conversion: bedaquiline (OR 9.62), linezolid (OR 8.15), cycloserine (OR 7.88), pyrazinamide (OR 7.29), moxifloxacin (OR 7.08), and ethambutol (OR 6.69). Ofloxacin demonstrated a confident negative effect on achieving sputum conversion (95% CI 0.06-0.32).
About the Authors
I. A. Vasilyeva
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Doctor of Medical Sciences, Professor, Director,
4, Dostoevsky St., Moscow, 127473
A. G. Samoylova
Research Institute of Phthisiopulmonology by I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Doctor of Medical Sciences, Deputy Director,
4, Dostoevsky St., Moscow, 127473
O. V. Lovacheva
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Doctor of Medical Sciences, Professor, Leading Researcher of Clinical Diagnostics Department,
2, Yauzskaya Alleya, Moscow, 107564
L. N. Chernousova
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Doctor of Biological Sciences, Professor, Head of Microbiology Department,
2, Yauzskaya Alleya, Moscow, 107564
T. R. Bagdasaryan
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Candidate of Medical Sciences, Head of First Therapy Department,
2, Yauzskaya Alleya, Moscow, 107564
References
1. Tuberkulez v Rossiyskoy Federatsii, 2012/2013/2014. [Tuberculosis in the Russian Federation, 2012/2013/2014]. Moscow, 2016. 312 p.
2. Abbate E., Vescovo M., Natiello M., Cufre M. et al. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with combination of linezolid, moxifloxacin and thioridazine. J. Antimicrob. Chemother., 2012, no. 67(2), pp. 473-477.
3. Ahuja S.D., Ashkin D., Avendano M., Banerjee R., Bauer M., Bayona J.N., Becerra M.C., Benedetti A., Burgos M., Centis R., Chan E.D., Chiang C. Y., Cox H., D'Ambrosio L. et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PLos Med., 2012, no. 9/8, pp. 1001-300.
4. Alcala L., Ruiz-Serrano M.J., Turegano Perez-Fernandez et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob. Agents Chemother., 2003, no. 47, pp. 416-417.
5. Caminero J., Sotgiu G., Zumla A. et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect. Dis., 2010, no. 10, pp. 621-629.
6. Cavalieri S.J., Biehle J.R., Sanders W.E.Jr. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis Antimicrob. Agents Chemother., 1995, no. 39 (7), pp. 1542-1545.
7. Chambers H.F., Sipit T., Kocago’z T. Activity of Amoxicillin/Clavulanate in patients with tuberculosis. Clin. Infect. Dis., 1998, no. 26 (4), pp. 874-877.
8. Chang K.C., Yew W.W., Tam C.M., Leung C.C. WHO Group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother., 2013, doi: 10.1128/AAC.00120-13.
9. Cox H., Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int. J. Tuberc. Lung Dis., 2012, no. 16 (4), pp. 447-454.
10. Fortun J., Martin-Davila P., Navas E., Perez-Elıas Ma J., Cobo J., Tato M., Gomez-G De la Pedrosa E., Gomez-Mampaso E., Moreno S. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrobial Chemotherapy, 2005, no. 56, pp. 180-185.
11. Garcia-Tapia A., Rodriguez J.C., Royo G., Ruiz M. Action of fluoroquinolones and linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis. Chemotherapy, 2004, no. 50, pp. 211-213.
12. Global tuberculosis report, 2016, WHO/HTM/TB/2016.13
13. Haruaki Tomioka. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Current Pharmaceutical Design, 2006, no. 12, pp. 4047-4070.
14. Iannini P.B. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opin Drug Saf., 2002, no. 1(2), pp. 121-128.
15. Jacobson K.R., Tierney D.B., Jeon C.Y., Mitnick C.D., Murray M.B. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin. Infect. Dis., 2010, no. 51(1), pp. 41791.
16. Lee M., Lee J., Carroll M.W., Choi H., Min S., Song T. et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis . N. Engl. J. Med., 2012, no. 367 (16), pp. 1508-1518.
17. Migliori G.B. Sotgiu G., Richardson D'Arcy M., Centis R., Facchini A., Guenther G., Spanevello A., Lange C. MDR-TB and XDR-TB: drug resistance and treatment outcomes. Eur. Respir. J., 2009, no. 34 (3), pp. 778-779.
18. Rodriguez J.C., Ruiz M., Lopez M., Royo G. Synergic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents, 2003, no. 21, pp. 354-356.
19. Sotgiu G., Centis R., D’Ambrosio L., Alffenaar J.W. et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur. Respir. J., 2012, no. 40 (6), pp. 1430-1442.
20. Tang S., Yao L., Hao X., Zhang X., Liu G., Liu X. et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur. Respir. J., 2015, no. 45 (1), pp. 161-170.
21. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. October 2016 revision. Geneva, World Health Organization, 2016.
22. Winters N., Butler-Laporte G., Menzies D. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. Eur. Respir. J., 2015, no. 46 (5), pp. 1461-1470.
Review
For citations:
Vasilyeva I.A., Samoylova A.G., Lovacheva O.V., Chernousova L.N., Bagdasaryan T.R. THE EFFECT OF DIFFERENT TB DRUGS AND ANTIMICROBIAL AGENTS ON THE EFFICIENCY OF TREATMENT OF TUBERCULOSIS PATIENTS WITH MULTIPLE DRUG RESISTANCE. Tuberculosis and Lung Diseases. 2017;95(10):9-15. (In Russ.) https://doi.org/10.21292/2075-1230-2017-95-10-9-15
Views:
1593
Email this article 